Clinical trials: sargramostim, completed
Malignant Melanoma, Metastatic
Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma
The study is an open-label, single arm single Center Phase II study to evaluate the safety and efficacy of the combination of Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF, Leukine) and Ipilimumab (Yervoy) as therapy…
- Trial name
- GIPI (NCT01363206)
- Testing
- Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), Ipilimumab
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Lynn E. Spitler, MD
Prostate Cancer
GM-CSF Before Surgery in Treating Patients With Localized Prostate Cancer
RATIONALE: Colony-stimulating factors, such as GM-CSF, may help the body build an effective immune response to kill tumor cells. Giving GM-CSF before surgery may be an effective treatment for localized prostate cancer.
- Trial name
- NCT00305669
- Testing
- sargramostim, immunohistochemistry staining method, immunological diagnostic method
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of California, San Francisco
Leukemia, Myelodysplastic Syndromes
Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
RATIONALE: Bexarotene may help cancer or abnormal cells become more like normal cells, and to grow and spread more slowly. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow…
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00425477
- Testing
- sargramostim, bexarotene, cytogenetic analysis
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Melanoma (Skin)
Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. PURPOSE: This randomized phase II trial is studying four different vaccines using melanoma peptides from cytotoxic T cells and…
- Trial name
- NCT00071981
- Testing
- incomplete Freund's adjuvant, melanoma helper peptide vaccine, multi-epitope melanoma peptide vaccine
- Where
- 65 sites in United States
- Volunteers
- 175 people
- Sponsor
- Eastern Cooperative Oncology Group
Pediatric Sepsis-induced MODS
GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS Study
This study is an open-label, multi-center, interventional trial in which children with sepsis-induced MODS undergo surveillance immune function testing beginning on Day 2 of MODS.
- Trial name
- GRACE (NCT03769844)
- Testing
- GM-CSF
- Where
- 8 sites in United States
- Volunteers
- 75 people
- Sponsor
- Nationwide Children's Hospital
Lymphoma
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Vaccines may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00004198
- Testing
- keyhole limpet hemocyanin, sargramostim, tumor cell-based vaccine therapy
- Where
- United States
- Sponsor
- University of Nebraska
Leukemia
Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients
The goal of this clinical research study is to see if Leukine(R) (sargramostim) improves the effectiveness of the pneumococcal vaccine, a medicine used to prevent pneumococcal pneumonia, in patients with chronic lymphocytic…
- Trial name
- NCT00323557
- Testing
- Sargramostim (GM-CSF), Pneumococcal Vaccine
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- M.D. Anderson Cancer Center
HIV Infections
Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP
The effectiveness of a vaccine can be improved by using a "prime boost strategy" or by using an adjuvant. A prime boost strategy is the administration of one type of vaccine (the primer) followed by the administration of another…
- Trial name
- NCT00076037
- Testing
- HIV CTL MEP administered with RC529-SE adjuvant, GM-CSF
- Where
- 7 sites in United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
B Cell Lymphoma, Follicular Lymphoma
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
The idiotype of the immunoglobulin on a given B cell malignancy (Id) can serve as a clonal marker, and a previous pilot study in lymphoma patients has demonstrated that autologous Id protein can be formulated into an immunogenic…
- Conditions
- B Cell Lymphoma, Follicular Lymphoma, Lymphoma
- Trial name
- NCT00001512
- Testing
- Id-KLH Vaccine, GM-CSF
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7
Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer
This phase I trial is studying the side effects and best dose of ipilimumab when given with sargramostim in treating patients with metastatic prostate cancer.
- Trial name
- NCT00064129
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS
To determine the impact of maintenance therapy in patients with MDS/AML in remission.
- Trial name
- NCT01700673
- Testing
- Azacitidine, Sargramostim
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as ketoconazole, may stop the adrenal glands from making androgens.
- Trial name
- NCT00309894
- Testing
- sargramostim, ketoconazole, therapeutic hydrocortisone
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- University of California, San Francisco
Appendicitis
The Safety and Pharmacokinetics of Intraperitoneal Administration in Patients Undergoing Appendectomy for Uncomplicated Appendicitis
The objective of this trial is to evaluate the safety of the intraperitoneal administration of the combination of fosfomycin, metronidazole, and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients undergoing…
- Trial name
- NCT03046758
- Testing
- A combination of fosfomycin, metronidazole and GM-CSF i.p.
- Where
- Denmark
- Volunteers
- 14 people
- Sponsor
- Herlev Hospital
COVID-19
A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
Study KIN-1901-2001 is a multi-center, adaptive, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of gimsilumab in subjects with lung injury or acute respiratory distress syndrome (ARDS)…
- Trial name
- NCT04351243
- Testing
- Gimsilumab
- Where
- 33 sites in United States
- Volunteers
- 227 people
- Sponsor
- Kinevant Sciences GmbH
Pulmonary Alveolar Proteinosis, Autoimmune
Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan
Objective: Determine the safety and efficacy of GM-CSF inhalation in patients with aPAP. Study Design: multi-center, randomized, double-blind, placebo- controlled, safety/efficacy study.
- Trial name
- NCT02835742
- Testing
- Sargramostim
- Where
- Japan
- Volunteers
- 78 people
- Sponsor
- Niigata University Medical & Dental Hospital
Breast Cancer
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003972
- Testing
- filgrastim, sargramostim, busulfan
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- Fred Hutchinson Cancer Center
Autoimmune Pulmonary Alveolar Proteinosis
Inhaled GM-CSF Therapy of Autoimmune PAP
This is a prospective, randomized, open-label, long-term, phase 2 study of inhaled granulocyte/macrophage-colony stimulating factor following whole lung lavage therapy in patients with autoimmune pulmonary alveolar proteinosis.
- Trial name
- NCT00901511
- Testing
- Baseline WLL, Sargramostim, Rescue WLL
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Metastatic Cancer, Sarcoma
Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma
RATIONALE: Inhaling aerosolized sargramostim before and after surgery may interfere with the growth of tumor cells and shrink the tumor so that it can be removed during surgery.
- Trial name
- NCT00066365
- Testing
- sargramostim, conventional surgery
- Where
- 93 sites in United States, Australia and 2 more
- Volunteers
- 49 people
- Sponsor
- Children's Oncology Group
HIV Infections, Cytopenias
Granulocyte-Macrophage Colony-Stimulating Factor and Zidovudine: A Phase I Study of Concurrent Administration in Patients With AIDS and Severe ARC
To administer colony-stimulating factor (GM-CSF) for 4 weeks to AIDS and advanced AIDS related complex (ARC) patients who have been receiving zidovudine (AZT) therapy, in order to obtain data on short-term effectiveness, safety…
- Trial name
- NCT00000711
- Testing
- Zidovudine, Sargramostim
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Melanoma
Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma
The primary objective of this study is to evaluate the safety and feasibility of administering an allogeneic GM-CSF-secreting lethally irradiated whole melanoma cell vaccine ("melanoma GVAX"), alone or in combination with low…
- Trial name
- NCT01435499
- Testing
- melanoma GVAX, Cyclophosphamide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins